Frequency of Metabolic Dysfunction Associated Fatty Liver Disease in Patients With Acute Coronary Syndromes

ConditionFatty Liver

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAssiut University

About this trial

Aim of the research is to assess frequency of MAFLD among patients with acute coronary syndromes (ACS).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Patients refused to participate.

Patients with history of alcohol or drug abuse.

Patients have hepatitis C or hepatitis B infection.

Patients have primary or secondary hepatic malignancies

Trial population

Any Patient above the age of 18 years presented with acute coronary syndromes {myocardial infarction (MI), non-ST elevation myocardial infarction (NSTEMI), unstable angina} underwent coronary angiography within admission.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

fibroscan
Device
Fibroscan examination with controlled attenuation parameter"CAP" (Echosens FibroScan ® Compact 530) for evaluation of steatosis and its degree (by CAP score) and fibrosis stage by liver stiffness measurement(LSM)

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

Assess frequency of MAFLD among patients with acute coronary syndromes (ACS).

patients with acute coronary syndrome will be evaluated if they have MAFLD and then we will know frequency of MAFLD among patients with acute coronary syndromes (ACS)

Time frame

baseline

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: